Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Prepaid Assets (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Prepaid Assets for 4 consecutive years, with $38.1 million as the latest value for Q4 2025.

  • Quarterly Prepaid Assets rose 57.13% to $38.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.1 million through Dec 2025, up 57.13% year-over-year, with the annual reading at $38.1 million for FY2025, 57.13% up from the prior year.
  • Prepaid Assets hit $38.1 million in Q4 2025 for NewAmsterdam Pharma, up from $1.5 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $38.1 million in Q4 2025 to a low of $1.2 million in Q3 2024.
  • Historically, Prepaid Assets has averaged $8.9 million across 4 years, with a median of $2.9 million in 2024.
  • Biggest five-year swings in Prepaid Assets: soared 282.78% in 2024 and later tumbled 34.76% in 2025.
  • Year by year, Prepaid Assets stood at $7.8 million in 2022, then dropped by 18.97% to $6.3 million in 2023, then skyrocketed by 282.78% to $24.3 million in 2024, then surged by 57.13% to $38.1 million in 2025.
  • Business Quant data shows Prepaid Assets for NAMS at $38.1 million in Q4 2025, $1.5 million in Q3 2025, and $1.5 million in Q2 2025.